SUPPLY CHAIN: Synmosa Biopharma’s Vaks tablets and Synpac-Kingdom’s Disartan 80mg were found to contain a cancer-causing ingredient from the same Chinese factory
Taipei Times
Date: Feb 17, 2019
By: Staff writer, with CNA
Two local pharmaceutical firms have issued recalls for blood pressure medication after
A box of Vaks 160mg blood pressure tablets is pictured in an undated handout.
Photo provided by the Food and Drug Administration
their drugs were found to contain potential carcinogens, the Food and Drug Administration (FDA) said, following similar recalls worldwide.
Taipei-based Synmosa Biopharma Corp (健喬信元醫藥生技) on Friday informed the agency that during a self-screening it had discovered that the active ingredient valsartan in its Vaks 80mg and Vaks 160mg tablets contained N-nitrosodimethylamine (NDMA), a substance suspected to increase the likelihood of cancer, the FDA said in a statement
The valsartan came from Tianyu Pharmaceutical Co (天宇), in China’s Zhejiang Province, and had the batch number 10230-160509, the agency said.
The recall, which is to continue until June, affects about 660,000 million tablets produced by Synmosa in three batches, with the numbers B26541, B24691 and B22371, the agency said. [FULL STORY]
